CANCER OF UNKNOWN PRIMARY SITE
Clinical trials for CANCER OF UNKNOWN PRIMARY SITE explained in plain language.
Never miss a new study
Get alerted when new CANCER OF UNKNOWN PRIMARY SITE trials appear
Sign up with your email to follow new studies for CANCER OF UNKNOWN PRIMARY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for mystery cancers: immunotherapy shows promise
Disease control CompletedThis study tested the immunotherapy drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a cancer that starts in an unknown location. Participants received the drug intravenously, and researchers measured how many saw their tumors shrink or disappear. The goal wa…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immunotherapy drug tested for mysterious cancers
Disease control CompletedThis phase 2 trial tested the drug sintilimab in 10 people with advanced cancer of unknown primary (CUP), a rare cancer where doctors cannot find where it started. Participants received sintilimab every 3 weeks for up to 24 months. The study measured how many patients' tumors shr…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Gene-Guided therapy may outperform chemo for mysterious cancers
Disease control CompletedThis study tested whether using a person's tumor genetic profile to choose treatment works better than standard chemotherapy for cancer of unknown primary (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either gene-guided therapy …
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC